Experimental pill aims to hold back recurrent brain tumors
NCT ID NCT06780930
Summary
This study is testing whether a daily pill called vorasidenib can slow down or stop the growth of recurrent low-grade brain tumors (gliomas) in Asian patients who have a specific genetic mutation. Participants will take either the drug or a placebo pill, and researchers will track how long it takes for the tumors to progress. The goal is to delay the need for more aggressive treatments like chemotherapy or radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital,
Taoyuan District, Taiwan
-
Huashan Hospital Fudan University
Shanghai, 200040, China
-
Sanbo Brain Hospital, Capital Medical University
Beijing, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The Second Affiliated Hospital of Air Force Military Medical University
Xi'an, China
-
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China
-
Tiantan Hospital
Beijing, 100070, China
-
West China Hospital Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.